MK-0616 - How near is an oral PCSK9i?
Professors John Chapman and Chris Packard consider the evidence supporting MK-0616 as potentially the first oral PCSK9i to reach the clinic.
Related reports:
Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia
MK-0616: Hope for an oral PCSK9 inhibitor?